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It is known that an increased oxidative stress is present in a wide range of diseases and, given the vulnerability of the central 
nervous system, its involvement has been in particular investigated in neurological and psychiatric diseases, including anxiety 
disorders. In this review we analyse the studies that have been conducted on the effects of oxidative stress modulators in 
anxiety, focusing on their possible clinical use. While preclinical studies have shown a clear anxiolytic-like effect of different 
oxidative stress modulators, less significant results have been obtained from clinical studies. After having reviewed the 
possible reasons for the discrepancy between preclinical and clinical data, we encourage further studies aimed at better 
investigating the utility of the modulation of oxidative stress in humans, as adjunctive therapy of the traditional integrated 
psychotherapeutic and pharmacological approach. 
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1.1. Anxiety disorders 
Anxiety disorders are the most common class of 
psychiatric disorders  [1, 2]. The Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5) divides 
them in: separation anxiety disorder, selective mutism, 
specific phobia, social phobia, panic disorder, 
agoraphobia, generalized anxiety disorder, anxiety 
disorder caused by use of substances, and anxiety 
disorder due to another medical condition  [3].  
Many epidemiological studies have shown that anxiety 
disorders typically start in childhood or in early adult 
age and tend to decrease in older age, with a median age 
of onset of 11 years  [4], and in the absence of proper 
treatment they can become chronic. Anxiety disorders in 
Europe have a twelve months and a lifetime prevalence 
of 8,4% and 14,8%, respectively, with prevalence being 
approximately twice higher in women than in men  [5]. 
They cause more loss of working days than other 
disorders of high social impact, with an economic 
burden of 41 billion Euros in the EU in 2004  [5]. 
Anxiety disorders are often in comorbidity with other 
psychiatric conditions, such as depressive disorders, 
drug and alcohol abuse, personality disorders, bipolar 
disorder  [6] and also with chronic medical conditions, 
such as diabetes  [7],chronic obstructive pulmonary 
disease  [8], thyroid dysfunction  [9] and coronary artery 
disease  [10].  
Amygdala and the insular cortex play a crucial role in 
the pathophysiology of anxiety  [11]; these brain regions 
are activated in response to fear in healthy individuals, 
and are hyperactive during the processing of negative 
emotions in patients with anxiety disorder  [11].  
Although different theories have been proposed, the 
etiology of anxiety disorders is still unclear  [12]. One 
theory suggests an association between the biochemical 
alterations caused by oxidative stress and anxiety, 
although a causal relationship between oxidative stress 
and anxiety has not been demonstrated, as yet.  
1.2. Oxidative Stress 
Oxidative stress is determined by the excessive 
production of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS)  [13]. Their deleterious 
action on proteins, DNA and lipids causes cell damage. 
1.2.1 Production and cellular effects of ROS 
The main cellular source of ROS is the mitochondrial 
respiratory chain, which is composed by five 
multisubunit protein complexes, and utilizes 
nicotinamide adenine dinucleotide (NADH), flavin 
adenine dinucleotide (FADH2), coenzyme Q (CoQ), 
and cytochrome c (Cyt c)as electron donors  [14]. 
Electrons are transferred one by one from the respiratory 
chain to O2, leading to the formation of superoxide 
anions (O2-.), which may leave the respiratory chain and 
can generate additional ROS species by interacting with 
other molecules  [15]. NADPH-oxidase (NOX), 
xanthine oxidase (XO), cyclooxygenase, lipoxygenase, 
epoxygenase, and cytochrome-P450 are additional 
sources of O2-. [16]. O2-.can be converted into hydrogen 
peroxide (H2O2) by copper-zinc superoxide dismutase 
(SOD1) in the cytosol and manganese superoxide 
dismutase (SOD2) in the mitochondria. The amount of 
O2-.that is not inactivated undergoes protonation into 
hydroperoxyl (HO2), which, in turn, causes lipid 
peroxidation. Hydrogen peroxide, which is also 
produced by peroxysomal enzymes is detoxified by 
catalase (CAT), glutathione peroxidase (GPx), and 
peroxiredoxins. Alternatively, hydrogen peroxide is 
converted into hydroxyl radicals (OH.) in the presence 
of Fe2+ (Fenton reaction). Fe2+ can be generated from 
reduction of Fe2+ in the presence of O2-..The net reaction 
leading to the formation of OH.and hydroxyl anions 
(OH-) is named Heber-Weiss reaction  [14, 17]. 
Hydroxyl radicals are powerful oxidizing agents, that 
can damage proteins, lipids, sugars and DNA [16].  
1.2.2 RNS and their cellular effects 
The RNS, nitric oxide (NO.) and peroxynitrite (NOOO-
), have gained popularity as intracellular and 
intercellular mediators, and may also cause cellular 
damage. Nitric oxide (NO) is synthesized from L-
arginine by NO synthase (NOS) isoenzymes  [18]. NO 
can compete with SOD for O2-., forming NOOO-, which 
can nitrosylate tyrosine residues in proteins  [19] leading 
to structural and functional protein changes  [20]; 
NOOO- can also cause lipid peroxidation and apoptotic 
death  [21, 22].  
1.2.3 Lipid peroxidation and its products 
Lipid peroxidation caused by ROS or RNS, represents a 
common mechanism of lipid damage. In this particular 
process, oxidants attack the lipids containing carbon-
carbon double bonds, like polyunsaturated fatty acids 
(PUFAs), glycolipids, phospholipids and cholesterol 
[23] . Lipid peroxidation is a chain reaction that once 
started continues until the formation of the final 
products. Lipid hydroperoxides are the main primary 
products of lipid peroxidation; alkens, ketones, and 
reactive carbonyl compounds are secondary products 
(RCCs) [23]. They include aldehydes, such as 
malondialdhyde (MDA) and 4-hydroxynonenal (4-
HNE), and α-oxalaldehydes, such as glyoxal and 
methylglyoxal  [24, 25]. These compounds may cause 
cytoxicity by promoting the formation of end glycation 
products or by damaging DNA, proteins, and membrane 
lipids  [26].  
 
2. Oxidative stress and anxiety in animal models 
In preclinical studies, anxiety-like behaviour can be 
induced by exposing animals to environmental stressors, 
such as restraint, predator odor, and social defeat, or 
alternatively, by a paradigm of fear conditioning, in 
which a neutral stimulus is associated with an aversive 
stimulus (for example, a red light with a foot shock). The 
resulting anxiety-like behaviour can be evaluated by 
conflicts tests, such as the elevated plus maze (EPM), 
the light-dark box (LD), or the open field (OF) test, in 
which the natural propensity of rodents to explore in an 
open space is in conflict with the vulnerability to threats; 
the most anxious animals have a reduced tendency to 
exploration compared to the average behaviour of their 
strain  [27].  
2.1 Evaluation of anxiety-like behaviour in models of 
genetically induced oxidative stress 
Lipid peroxidation products can be metabolized by 
enzymatic detoxification systems. For example, α-
oxalaldehydes are detoxified by the glyoxalase system, 
composed by the enzymes glyoxalase 1(Glo1) and 
glyoxalase 2, and by reduced glutathione (GSH). 
Glyoxalase 1 has a broad substrate spectrum for 
oxoaldehydes and catalyses the reaction that leads to 
lactoylglutathione from the emithioacetal produced non 
enzymatically by the binding of an oxoaldehyde and a 
reduced GSH molecule  [28]. Glyoxalase 2, regenerates 
reduced GSH by the hydrolysis of lactoylglutathione 
into lactic acid  [29]. Since the study of Hovatta et al 
(2005), mice with genetic manipulation of detoxifying 
enzymes have been widely used for the investigation of 
the correlation of oxidative stress and anxiety-like 
behaviour. Hovatta et al. examined the correlation 
between Glo1 and glutathione reductase 1 (Grs1) genes 
with anxiety-like behaviour. They found an increased 
expression of Glo1 in mouse strains with high levels of 
anxiety; in addition, lentiviral vector-induced 
overexpression of Glo1 and Grs1 in the cingulate cortex 
caused an increased anxiety-like behaviour, whereas a 
reduced anxiety was seen after Glio1 gene silencing  
[30]. In contrast, Krömer et al., using outbred CD1 mice, 
found an association between low level of anxiety and 
increased expression of Glo1 in the hypothalamus, 
amygdala and motor cortex  [31], and in peripheral red 
blood cells  [32].  
A study by Williams et al. shows evidence that 
variability of Glo1 expression in mice is the result of a 
common duplication of a large genomic region 
including the Glo1 gene. Gene duplication is associated 
with increased Glo1 expression and anxiety-like 
behaviour both in inbred and outbred CD1 mice  [33], in 
agreement with findings obtained by Hovatta et al.  [30]. 
It has been proposed that methylglyoxal induced 
neuronal damage may be a critical determinant in the 
high- or low-anxiety behaviour seen in different studies.  
[34] 
Using transgenic mice, Distler et al. found that 
Glo1caused an anxiolytic effect by reducing the 
formation of methylglyoxal, thereby activating GABAA 
receptors  [35]. Moving from these findings, it has been 
proposed that Glo1 may represent a putative drug target 
in the treatment of anxiety disorders  [36], although the 
precise role played by Glo1 in the pathophysiology of 
anxiety should be the subject of further investigation  
[35] .  
2.2 Evaluation of anxiety-like behaviour in models of 
oxidative stress induced by chemical compounds 
Other studies have employed rodent models of oxidative 
stress based on the use of oxidative stress inducers. 
Masood et al treated mice with buthionine sulfoximine 
(BSO), an oxidative stress inducer that depletes GSH, 
and found an increase in anxiety-like behaviour 
evaluated in the EPM and OF. Knowing that the NO-
cGMP signalling influences anxiety-like behaviour, 
they also investigated if phosphodiesterase-2 (PDE-2) 
inhibitors could impact the association between anxiety-
like behaviour and oxidative stress. They found that 
PDE inhibitors could restrain the anxiogenic effect of 
oxidative stress by increasing c-GMP signalling, while 
administration of diazepam was ineffective. They also 
found that the anxiety-like behaviour induced by BSO 
was antagonized by the NOX2 inhibitor apocynin  [37].  
Salim et al. found that subchronic but not acute 
treatment with BSO in rats increased anxiety-like 
behaviour, and this correlated with the presence of 
oxidative stress biomarkers in the serum, urine, 
amygdala, and locus coeruleus  [38]. In a different study, 
the same Authors reported that BSO administration in 
rats decreased the expression of Glo1 and Gsr1 and 
induced the expression of ERK1/2 in the amygdala, 
cerebral cortex and hippocampus  [39], in agreement 
with previous studies that showed the involvement of 
the ERK 1/2 pathway in anxiety  [40, 41].  
2.3 Evaluation of oxidative stress in models of innate 
and conditioned anxiety 
Further evidence supporting the correlation between 
anxiety and oxidative stress was obtained with animal 
models of innate and conditioned anxiety in which 
different parameters of oxidative stress were evaluated. 
Hassan et al used two lines of rats, characterized by a 
different freezing response to fear conditioning, named 
“Carioca high- and low-conditioned freezing”(CHF and 
CLF). In the CHF line, the concentrations of free 
radicals and MDA were higher in the hippocampus, 
cerebellum, and cerebral cortex, CAT activity was 
decreased in hippocampus and cortex, and GPx activity 
was decreased in all three structures, as compared to the 
CLF line  [42].  
A following study showed that administration of 
diphenyl diselenide, a compound endowed with 
antioxidant propriety, caused a reduction of freezing in 
anxious rats  [43].  
In rats, exposure to a predator odor caused an increased 
ROS production and SOD activity in the amygdala, and 
an increase in SOD activity only in the prefrontal cortex 
and hypothalamus  [44]. In another study in which 
exposure to predator odor was associated to 
psychosocial stress, ROS levels were significantly 
elevated in the hippocampus and prefrontal cortex of 
stressed animals  [45].  
The role of RSN in anxiety was examined in a model of 
social isolation. Nitrite levels were increased in the 
hippocampus and cortex of stressed mice, and 
administration of NOS inhibitors reversed anxiety-like 
behaviour induced by social isolation  [46]. Increased 
nitrosative stress was also found in restrain stress model 
of anxiety  [47].  
 
3. Oxidative stress in patients with anxiety and other 
psychiatric disorders 
The Central Nervous System (CNS) is highly vulnerable 
to oxidative stress for the following reasons  [48]: (i) the 
brain has a high oxygen consumption (about 20% of the 
assumed oxygen)  [49]; (ii) neuronal membranes are rich 
in PUFA, which are susceptible to lipid peroxidation  
[50]; (iii) antioxidant defences are less efficient in the 
CNS than in other organs because of a lower expression 
of CAT, GSH-peroxidase, GSH and vitamin E  [51]; 
and, (iv) intracellular iron accumulates in neurons of the 
aged brain  [52]. 
The knowledge that the human brain is particularly 
vulnerable to oxidative stress stimulated the search for 
peripheral markers of oxidative in the blood of patients 
with psychiatric disorders, such as anxiety  [49]. A 
clinical study evaluated oxidative stress in patients with 
generalized anxiety disorder (GAD), by measuring the 
total oxidative status (TOS), the total antioxidant status 
(TAS) and the ratio between TOS and TAS, which is the 
oxidative stress index (OSI). They found that TOS and 
OSI were significantly higher in patients affected by 
GAD than in healthy controls, while TAS was lower  
[53].  
Increased levels of lipid peroxidation markers have also 
been found in patients with anxiety disorders  [13]. 
Atmaca et al found increased MDA levels, and an 
increased activity of SOD, CAT, and GPx in patients 
with social phobia  [54]. Increases in MDA levels, 
depletion of GSH, vitamins A and E, and increased SOD 
and GPx activity were found in patients suffering of 
panic attacks  [55, 56]. In contrast, Hagan et al., in a 
cross-sectional study of 1,325 women, did not find an 
association between phobic anxiety and plasma 
fluorescent oxidation products (FLOPs), which are non-
specific markers of global oxidative stress originating 
from the interaction of ROS with macromolecules  [57]. 
In children with anxiety disorder Ceylan et al. found 
higher serum levels of lipid hydroperoxide (LOOH) as 
compared to healthy controls with no changes in the 
activity of the antioxidant enzymes, paraoxonase and 
arylesterase  [58]. A similar increase in plasma LOOH 
levels was reported in adult patients affected by GAD. 
These patients also showed a reduced activity of 
paraoxonase  [59]. 
Patients with depression, anxiety and alcohol abuse 
show increases in pro-inflammatory cytokines 
associated with an increased activity of transcription 
factors, such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kβ) and the cAMP 
response element-binding protein (CREB); these factors 
regulate the expression of inflammation related 
enzymes, like cyclooxygenase-2 (COX-2), NOS and 
NADPH-oxidase, which are involved in ROS 
production  [13]. 
4. Oxidative stress modulators 
Despite OS is only one of the multiple mechanisms 
involved in the pathophysiology of anxiety disorders, 
OS modulation may provide a novel strategy for add-on 
treatment of anxiety, as highlighted by numerous 
observations. 
4.1 Mechanisms of action of oxidative stress modulators 
 
OS modulators act via different mechanisms that may 
operate simultaneously.  
One of the best documented antioxidant mechanism 
consists in a direct free radical scavenging and metal 
chelation. This, for example, is characteristic of 
polyphenols, whose activity, however is, limited by their 
low central bioavailability  [60].  
An indirect antioxidant action can instead be exerted 
through the induction on the enzymatic antioxidant 
system. Induction of antioxidant enzymes follows the 
activation of the Nuclear factor (erythroid-derived 2)-
like (Nrf2) pathway. Nrf2 is a transcription factor that 
drives the expression of several detoxification and 
antioxidant enzymes. Under basal conditions, Nrf2 is 
sequestered in the cytoplasm by Keap1, which acts as a 
substrate adaptor protein for the Cul3-containing E3 
ligase that promotes Nrf2 ubiquitination and proteasome 
degradation  [61]. Keap1 also acts as a sensor for 
oxidative and electrophile stress. Under OS conditions 
some critical cysteine residues of Keap-1 are covalently 
modified, causing a conformational change of the 
protein, which disrupts its interaction with Nrf2. As a 
result, Nrf2is not degraded and translocates into the 
nucleus, where it heterodimerizes with Maf proteins and 
binds to antioxidant sequence elements (AREs) 
sequences inducing the transcription of many drug-
metabolizing and antioxidant enzymes. Nrf2 is highly 
expressed in the CNS and a defective activation of Nrf2 
has been associated to chronic neurological diseases  
[62]. Data obtained in experimental animals suggest that 
the Nrf2 pathway plays a role in anxiety disorders. 
Intracerebroventricular injection of Nrf2 siRNA in adult 
Wistar rats increased anxiety-like behaviour associated 
with an increased Bax/Bcl ratio in the hippocampus, 
amygdala, and prefrontal cortex  [63]. Nrf2 activation 
has been shown to be a common mechanism of action of 
several antioxidants, such as curcuminoids, quercetin, 
epigallocatechin gallate, resveratrol, N-acetylysteine 
and ebselen. However, the risk-to-benefit ration should 
be carefully evaluated when using Nrf2 activators. For 
example, Nrf2 activation may promote tumour growth 
and cancer cell resistance to chemotherapy  [64]. 
Another indirect antioxidant mechanism is the 
modulation of the activity of sirtuins, a family of seven 
proteins (SIRT1-7) that act as epigenetic regulators, and 
are involved in a wide range of cellular processes, 
including oxidative stress  [65]. In particular, SIRT1 and 
SIRT3 are primarily involved in OS regulation  [66]. 
SIRT1 has both cytoplasmic and nuclear localization 
and it mediates the deacetylation and activation of 
different transcription factors and co-activators of genes 
encoding for antioxidant proteins. Among its targets 
there are the transcription factors of the forkhead box 
class O (FoxO) family, which regulate the expression of 
SOD2 and the peroxisome proliferator-activated 
receptor co-activator 1-α (PGC-1α), which in turn 
regulates the expression of GPx1 and CAT. 
Furthermore, SIRT1 may deacetylate the p65 subunit of 
NF-kB, with ensuing suppression of inducible nitric 
oxide synthase (iNOS). SIRT3 is instead mainly 
localized in the mitochondria, where it deacetylates and 
activates SOD2  [66]. 
Because sirtuins have a widespread role in the regulation 
of cellular processes, the use of their activators and 
inhibitors may prove useful in different therapeutic 
areas. In anxiety disorders, although SIRT1 activation 
exerts antioxidant activity, it may increase anxiety, 
through other mechanisms such as monoamino oxidase 
A (MAO-A) activation  [67]. This may help explain the 
contrasting data obtained with resveratrol, a SIRT1 
activator, in the treatment of anxiety.  
4.2 Polyphenols 
4.2.1 Quercetin 
One of first review about the neuroprotective properties 
of food plants, including quercetin, was written by 
Aruoma and published in 2003  [68].Lu et al. found that 
quercetin reversed the neurotoxic effect of D-galactose 
in the mouse brain, maintaining Ca2+ homeostasis and 
increasing the transcript of the neural growth-associated 
protein GAP43. Quercetin also reduced anxiety-like 
behaviour in the OF and corrected the D-galactose-
induced impairments in the “step-through” and Morris 
Water Maze tasks  [69]. Afterwards, Kumar and Goyal 
studied the effects of quercetin on the biochemical and 
behavioural modifications induced by an 
immobilization acute stress in mice. Quercetin 
administration prior to exposure to stress reduced 
anxiety-like behaviour, lowered MDA and nitrite levels, 
and restored the activity of antioxidant enzymes  [70]. In 
a similar experiment, Toumi et al. administered 
quercetin to pregnant rats prior to the exposure to 
predator odor. Quercetin pre-treatment reduced stress-
induced activation of the hypothalamic-pituitary-
adrenal (HPA) axis, attenuated oxidative stress in the 
dam brain, and decreased maternal anxiety  [71].  
Quercetin was also effective in reducing stress-induced 
depression and the associated increase in hypothalamic 
corticotropin-releasing factor (CRF) mRNA levels  [72]. 
It has been hypothesized that quercetin restrain the 
anxyogenic and pro-depressant effects of CRF  [73]. 
Accordingly, quercetin and the CRF receptor antagonist, 
antalarmin, produced synergistic anxyolitic and 
antidepressant effects perhaps through the modulation 
of OS  [74].Quercetin administration was also shown to 
be protective against toxicity induced by heavy metals, 
such as aluminium  [75] or cadmium  [76]. Exposure to 
both agents caused a reduction in acetylcholinesterase 
(AChE) activity and ATP levels in the rat brain andan 
impairment in cognitive and behavioural tasks 
associated with an increased anxiety-like behavior. 
Quercetin treatment could reverse all these pathological 
changes. The effects of quercetin were ascribed to its 
ability to reduce OS, thus protective cell membranes and 
associates enzymes against oxidative damage. 
Quercetin has been shown to rescue anxiety-like 
behaviour also in a model of neurotoxicity induced by 
polychlorinated biphenyls (PCBs) in adult rats. 
Quercetin also reduced PCB-induced ROS formation, 
hippocampal damage, and abnormalities in 
neurotransmitter levels  [77]. 
Other studies have shown that the anxiolytic and pro-
cognitive effects of quercetin are associated with 
changes in brain levels of GABA [78] and serotonin  
[79]. Quercetin, like other flavonoids, acts also as a 
Monoamino Oxidase A  inhibitor  [80–83].  
4.2.2 Ginkgo biloba: EGb 761 and ginkgolides 
Ginkgo biloba is a very ancient plant, and its fruits, 
seeds, and leafs have been widely used by traditional 
medicine  [84]. Currently the extract EGb 761 of Ginkgo 
biloba leaves is primarily used to improve memory and 
other potential therapeutic uses are under investigation. 
The extract has numerous pharmacological activities 
mediated, inter alia, to terpenes and flavonoids.  
Animal studies have shown that EGb 761 displays 
antidepressant/anxiolytic effects, described as anti-
stress or stress-alleviating  [85]. A first evidence for the 
anti-stress action of EGb 761 has been provided in 1990 
by Porsolt, using the “learned helplessness” and other 
models of stress in rodents. Data showed that 
administration of EGb 761 was effective in reducing the 
deficit in avoidance response in the learned helplessness 
paradigm, and its efficacy was greater when 
administered prior to the induction of stress. Moreover, 
in the emotional hypophagia test, EGb 761 
administration increased the amount of food consumed 
by rodents, showing an anxiolytic-like activity  [86]. An 
anti-stress effect of EGb 761 has also been demonstrated 
in mice undergoing a learning discrimination task. 
Exposure to stress during the discriminative phase of 
learning had negative effects on learning and caused an 
increase in epinephrine, norepinephrine and 
corticosterone plasma levels. Treatment with EGb 761 
for 20 days could reduce all these changes  [87]. Amri et 
al. showed that treatment with EGb 761 or its 
components, ginkgolides A and B, reduced mRNA and 
protein levels of peripheral benzodiazepine receptors 
(PBRs) in mitochondria of the adrenal gland. Because 
PBR regulates the transport of cholesterol across 
mitochondrial membranes, a lower PBR expression 
reduces the synthesis of corticosterone (corticosteron in 
rodents is the equivalent of cortisol in humans) and other 
adrenal hormones in the adrenal gland  [88]. Moving 
from these findings, Marchilac et al. further investigated 
the effects of EGb 761 on the response of the 
hypothalamus-pituitary-adrenal (HPA) axis to stress. 
Mice were exposed to surgical stress, which caused the 
expected increase in CRH, ACTH, and corticosterone 
levels. Treatment with 100 mg/kg of EGb 761 50mg/kg 
restrained the activation of the HPA axis and also 
reduced the increase in circulating catecholamine levels 
induced by surgical stress  [89].  
A series of studies examined the effect of Ginkgo Biloba 
extracts on anxiety-like behaviour and social behaviour 
in rodents. Low doses of Zingicomb (ZC), a 
combination of extracts of Zingiber Officinalis and 
Ginkgo Biloba, behaved similarly to diazepam in 
produced anxiolytic-like effects in rats  [90]. In contrast, 
systemic treatment with EGb 761 reduced social 
interaction in rats, which might be indicative of an 
anxiogenic activity of EGb 761. Of note, however, the 
anxiolytic action of diazepam was greater in animals 
pretreated with EGb 761. In addition, pretreatment with 
EGb 761 reversed the reduction of social interaction 
caused by β-carboline-3-carboxylic acid ethyl ester (β-
CCE), which behaves as a partial inverse agonist at the 
benzodiazepine site of GABAA receptors. The complex 
interaction with diazepam and β-CCE suggests that EGb 
761 modulates the activity of GABAA receptors  [85, 
91].  
A subsequent study showed that bilobalide, a terpene 
lactone component of EGb 761, act as a competitive 
GABAA receptor antagonists, and this can be the basis 
of its vigilance-enhancing and antidepressant-like 
activities of EGb 761 [92].  
Preclinical data laid the groundwork for the study of 
Ginkgo Biloba extracts in humans. Several randomized, 
placebo-controlled, double-blind, clinical trials have 
been conducted on the effects of EGb 761 on 
neuropsychiatric symptoms in patients with Alzheimer 
Disease (AD), vascular dementia (VaD), or mixed forms 
of dementia. In one study, patients were treated daily 
with either EGb 761 or placebo for at least 20 weeks, 
and changes in the Neuropsychiatric inventory (NPI) 
composite score and NPI caregivers distress score were 
considered as primary endpoints. Data showed that the 
NPI composite score improved after treatment with EGb 
761, and EGb 761 was significantly superior to placebo 
in improving neuropsychiatric symptoms, associated 
with dementia, including anxiety [93].  
The efficacy of EGb 761 was also examined in patients 
with primary anxiety disorders. In 2006, Woelk et al 
conducted a randomized, double-blind, placebo-
controlled trial to evaluate the effect of the extract EGb 
761 on generalized anxiety disorder(GAD) or 
adjustment disorder with anxious mood (ADWAM). 
The study included 107 patients, randomized to receive 
either EGb 761 or placebo for 4 weeks. The first 
endpoint of the study was the evaluation of anxiety 
through the Hamilton rating scale for anxiety (HAMA). 
Secondary endpoints were assessed through the list of 
complaints B-L', the Erlangen anxiety tension and 
aggression scale (EAAS), the clinical global impression 
and a global self-rating of perceived changes. The 
results showed that HAMA scores decreased 
significantly in patients treated with EGb 761 compared 
with patients treated with placebo and the effect was 
dose- dependent. The same result has occurred for 
secondary outcomes. The authors therefore suggest that 
Ginkgo Biloba extracts may be useful for the treatment 
of anxiety associated with cognitive impairment in the 
elderly as well as for the treatment of GAD in young 
people [94].  
4.2.3 Curcumin 
Curcumin (diferuloylmethane) is a phenolic compound 
extracted from the rhizome of the plant Curcuma Longa 
L. Several studies have demonstrated that curcumin has 
antioxidant, anti-inflammatory and antitumor properties 
[95].  
Some studies have found that curcumin is also endowed 
with anxiolytic activity.  
Interestingly curcumin reverses anxiety-like behaviour 
caused by acute lead exposure  [96] and acute 
immobilization stress [97]. Interestingly, acute stress 
was associated with lipid peroxidation, increased SOD 
activity, decreased CAT activity, and a compensatory 
increase in GPx activity. Curcumin treatment corrected 
all these abnormalities, raising the interesting possibility 
that antioxidants may be useful for the treatment of 
stress-induced anxiety. 
The anxiolytic-like effect of curcumin in rats was also 
shown by Patel et al, who showed that curcumin has 
synergistic effects with amitriptyline in relieving 
depression and anxiety  [98]. 
Curcumin was shown to enhance docosahexaenoic acid 
(DHA) synthesis in liver cells and to up-regulate the 
expression of DHA-synthesizing enzymes in the liver 
and brain when combined with dietary α-linolenic acid. 
Interestingly, this effect was related to the anxiolytic 
activity of curcumin  [99]. Other studies suggest that the 
anxiolytic activity of curcumin cannot be exclusively 
explained by its antioxidant properties, but involves 
additional mechanisms, such as changes in monoamine 
levels in the CNS  [100]. Accordingly, curcumin 
treatment could reverse changes in monoaminelevels 
induced by olfactory bulbectomy, which is a validated 
animal model of depression [101].  
The antianxiety-like effect of curcumin has also been 
shown in mice. Gilhotra and Dhingra showed that 
curcumin, at a dose of 20 mg/kg, produced antianxiety-
like effects in mice exposed to restraint stress. The 
action of curcumin was potentiated by pretreatment with 
the iNOS inhibitor, aminoguanidine, but not with the 
nNOS inhibitor, 7-nitroindazole [102]. This study 
moved from the evidence that curcumin relieved anxiety 
and attenuated oxidative damage induced by sleep 
deprivation in mice. These effects were prevented by the 
nitric oxide precursor, L-arginine, and were potentiated 
by the NOS pseudosubstrate, L-NAME  [103].  
The anxiolytic effect of curcumin was also investigated 
in humans. A randomized controlled clinical trial was 
conducted in the Nutrition Clinic at the Ghaem Hospital 
of Mashhad, Iran, in thirty obese patients. Patients were 
randomized to receive curcumin or placebo for 30 days, 
and then, after a wash-out period of 2 weeks, they were 
crossed-over to the alternative regimen for 30 more 
days. They were assessed for anxiety and depression 
with the Beck Anxiety Inventory (BAI) scale and Beck 
Depression Inventory (BDI) scale. This study showed 
that subjects supplemented with curcumin had lower 
scores on the BAI, but not on the BDI scale, suggesting 
a potential anxiolytic activity of curcumin in obese 
individuals. However, this was a sub-study of an 
investigation of the effects of curcuminoids on 
cardiovascular risk markers, and the presence of anxiety 
and depression was not considered as an inclusion 
criterium .In addition, no measurements of curcuminoid 
levels in the plasma were performed, and the sample size 
was small  [104].  
Despite the great amount of studies on its beneficial 
effects, it has been shown that curcumin can pertubate 
cellular membranes, giving rise to false protein binding 
signals and its therapeutic use is limited by its short half-
life and poor biovailability  [105]. Recently it has been 
identified both as a possible invalid metabolic panacea 
(IMP), molecule that seems to have curative proprieties 
but gives no results in clinical trials, and as a PAINS, 
pan-assay interference compound, a compound that 
shows activity in different assays by interfering with 
their readout. [106]  
 
4.2.4 Epigallocatechin gallate (EGCG) 
EGCG is the most represented and powerful antioxidant 
contained in green tea. Although it has no therapeutic 
indications, there are many preclinical studies that show 
its neuroprotective effect in animal models of 
neurodegenerative diseases [107]. For example, it may 
exert neuoprotective activity against ischemic injury by 
scavenging ROS and blocking lipid peroxidation  [108], 
and reduce excitotoxic neuronal death in in vitro models  
[109]. Recent observations suggest that EGCG regulate 
mechanisms of oxidative deamination, which generate 
protein carbonyl cross-reacting with IgM, and allow the 
scavenging of damaged molecules  [110].  
EGCG, like other flavonoids  [111], could also have an 
effect on GABAA receptors, as shown by behavioural 
studies in mice  [112]. Along this line, EGCG was able 
to reverse the anxiogenic-like effects of caffeine, as 
shown by a reduction the time spent by the animals in 
the open arms of the EPM  [113].  
A clinical trial (NCT00981292) has been conducted to 
evaluate the effect of EGCG on cognitive function and 




4.3.1 Vitamin C 
Vitamin C or ascorbic acid (AA) is a water-soluble 
antioxidant capable of reducing reactive free radicals by 
donating electrons and terminating the lipid 
peroxidation chain reaction. After the transfer of an 
electron,vitamin C forms an ascorbyl radical, a free 
radical species that is relatively stable and therefore less 
harmful. Hence, it acts as a radical scavenger or 
quencher, by forming a less reactive radical species 
instead of a more reactive species. Vitamin C can also 
regenerate vitamin E (α-tocopherol) by reducing 
tocopheroxyl radicals  [115, 116]. 
A randomized controlled clinical trial by Brody et al. 
assessed the efficacy of high doses of ascorbic acid on 
the response to an acute stress [117]. The 120 
participants underwent the Trier Social Stress Test 
(TSST), a paradigm of psychosocial stress, composed of 
two phases, one of anticipation and one of testing, 
during which the subject had to make a free speech and 
perform mental arithmetic publicly. They were 
randomized to receive placebo or ascorbic acid for a 
period of 14 days. The results have shown that ascorbic 
acid mitigated the physiological responses of systolic 
and diastolic blood pressure and cortisol to stress. 
Furthermore, subjects in the ascorbic acid group showed 
less anxiety, as assessed by the Spielberg State Anxiety 
Scale, both before and after stress. 
Subsequently, Mazloom et al conducted a randomized, 
single-blind, placebo-controlled clinical trial to 
investigate the efficacy of vitamin C and E 
supplementation on anxiety, depression and stress 
associated with type--2 diabetes. The trial involved 45 
patients with type-2 diabetes, randomized to receive 
vitamin C, vitamin E or placebo for six weeks. The 
DASS-21 scale (Depression Anxiety Stress Scales 21-
items) was used for patient evaluation. Patients 
receiving vitamin C showed reduced levels of anxiety, 
with no changes in depression  [118]. 
The effect of vitamin C has been further investigated by 
de Oliveira, who conducted a double-blind, placebo-
controlled, randomized clinical trials on 42 high school 
students. Treatment with vitamin C decreased anxiety, 
as, assessed by the Beck Anxiety Inventory, and this was 
correlated with plasma Vitamin C levels; in addition, 
there was a significant difference in the heart rate 
between the two groups  [119]. This clinical trial further 
supported the anxiolytic effect of Vitamin C in humans. 
4.3.2 Vitamin E 
Vitamin E (α-tocopherol) is a lipid soluble antioxidant 
that also act terminating the lipid peroxidation chain 
reaction.  
Both animal that human studies have shown that a 
chronic severe deficiency of vitamin E determines the 
onset of ataxia [120–122].This finding generated further 
studies on the effects of vitamin E deficiency [123]. 
A study by Goheil showed that, in α-Tocopherol 
Transfer Protein (α-TTP) knock-out mice, it also 
occurred a decrease in some behavioural parameters 
related to anxiety: mice moved shorter distances and 
spent less time in the open arms of the EPM and have 
less rearing behaviours. These results are consistent with 
an increased anxiety in α-TTP knock-out mice [124].  
Another animal model of vitamin E deficiency are 
knock-out mice for the gene coding for the Phospholipid 
Transfer Protein (PLTP). This protein, widely expressed 
in the brain, probably acts as a α-tocopherol transfer; its 
absence therefore correlates to low vitamin E 
concentrations in the brain. PLTP-knock-out mice 
showed an anxious-like behaviour in the EPM, indicated 
by a smaller number of entries and less time spent in the 
open arms [125].  
These two experiments have thus shown that a 
congenital vitamin E deficiency is linked to an increased 
anxious-like behaviour in mice.  
An experiment by Terada investigated whether vitamin 
E deficiency in juvenile or adult rat was similarly 
correlated to an anxious behaviour. A 4 weeks 
administration of a vitamin E-depleted diet had an 
anxiogenic effect, assessed through the EPM, both in 
juvenile and adult rats. Vitamin E deficiency was also 
associated with an increase in tissue and plasma lipid 
peroxidation, in both juvenile and adult rats. In addition, 
in vitamin E deficiency there was an increase of 
corticosterone concentrations under the EPM stress. 
Therefore, anxiety related to vitamin E deficiency 
seemed to be linked to increased oxidative stress and 
elevated corticosterone plasma concentrations  [120]. 
However in other studies the α-tocopherol has been 
reported to be anxiogenic in Wistar rats at the EPM test 
[125, 126]. This could be due to a different action of 
vitamin E from the antioxidant effect. 
4.4 Thiol agents 
4.4.1 N-acetylcysteine (NAC) 
N-acetyl cysteine (NAC) is a derivative of the amino 
acid cysteine [127], with initial main indication as an 
antidote to paracetamol intoxication, as a mucolytic 
agent in chronic obstructive pulmonary disease and 
cystic fibrosis and as a renal protector in contrast-
induced nephropathy [128]. Over the past decade it has 
also been paid much attention to the use of NAC in the 
treatment of neuropsychiatric disorders  [129]. Among 
the actions exerted by NAC in these disorders, there is 
the antioxidant one. NAC has a weak direct antioxidant 
effect due to the presence of a free thiol group capable 
of interacting with the electrophilic group of ROS [130, 
131]. Its principal antioxidant mechanism of action, 
however, is the indirect one, as precursor of GSH, one 
of the most important intracellular antioxidant agents. 
GSH is a tripeptide formed from glutamic acid, cysteine 
and glycine, synthesized in the cell cytoplasm, in a 
manner dependent on the cellular availability of cysteine 
and on the activity of the enzyme glutamate cysteine 
ligase (GCL) [132]; NAC can easily cross the cellular 
membrane and inside the cell it is deacetylated to 
cysteine, used for the synthesis of GSH [130]. The 
intracellular entry of the NAC at the level of the central 
nervous system is mainly linked to the amino acid 
transporter C1 (ECAAC1) and, in the astrocytes, also to 
the cystine/glutamate (Xc-) antiporters; [133] through 
the latter, NAC derived cysteine can lead to an increased 
glutamate release from the astrocytes, that permits the 
activation of the Gi-coupled metabotropic glutamate 
receptors, with subsequent influence also on dopamine 
release [133, 134]. 
Furthermore, some studies have shown that NAC is able 
to reduce neuroinflammation probably inhibiting 
microglia and the production of proinflammatory 
cytokines and oxidative species by the same. [135] 
The discovery of the influence of NAC on oxidative 
stress, neuroinflammation and monoamine transmission 
has increased the interest to its use in the treatment of 
neuropsychiatric disorders, as all these mechanisms are 
involved in their pathogenesis. In recent years, several 
clinical trials have been conducted on these disorders 
using NAC as adjunctive treatment and the results were 
generally positive, although the data are still limited. 
Among the psychiatric disorders examined there are 
addiction, schizophrenia, bipolar disorders, obsessive 
compulsive and related disorders, as trichotillomania, 
skin-picking and nails biting [131]; after a trial on 
patients with substance abuse and post traumatic stress 
disorder (NCT02499029) [136], another trial on post-
traumatic stress disorders is currently recruiting patients 
(NCT01664260) [137]. 
With regard to the topic of interest of this article, Strawn 
and Saldaña reported the case of a 17 year boy with 
GAD and social phobia, affecting the normal proper 
functioning of the person, only partially responding to 
treatment with high doses of sertraline; the addition to 
therapy of NAC 1200 mg twice a day was followed by 
significant improvement of both psychic and somatic 
anxiety symptoms [138] . A preclinical study on 
zebrafish has shown that NAC prevented the anxiety-
like behaviours induced by an acute stressor and 
increased the time spent by the animals in the lit side in 
the LD test  [139]. A recent study has shown an 
anxiolytic-like effect of NAC in mice in the light-dark 
box and the open field test  [140]. These preclinical 
findings lay the groundwork for the study of NAC in 
patients affected by anxiety disorders. 
4.5 Metals 
4.5.1 Selenium 
Selenium is a trace element present in food, essential in 
human diet. Although selenium deficiency is rare, its 
decreased blood concentration has been associated for 
many years with different pathological conditions [141]; 
thus, numerous studies have been conducted to evaluate 
the preventive or therapeutic effect of selenium 
replacement therapies  [142]. 
Selenium has antioxidant property, both by itself and 
through its metabolites, but their short half life limits the 
possibility of quantifying their therapeutic effectiveness 
[143]. It can act as a cofactor for some antioxidant 
enzymes, such as GPx and to take advantage of this 
property different organoselenium compounds have 
been recently developed  [144]; these include diphenil-
diselenide, which has been shown to reduce anxiety-like 
behaviour in EPM and in contextual fear condition in 
rats treated with monosodium glutamate  [145]. 
A clinical study on selenium supplementation in 
HIV/AIDS affected patients has shown that, after 12 
months, treated patients reported less anxiety compared 
to the control group, suggesting that it could be useful in 
these patients to alleviate the anxiety associated with the 
disease  [146].  
4.6 Synthetic antioxidants 
4.6.1 Edaravone 
Edaravone is an antioxidant molecule developed in 
Japan and commercialized in Japan and India. It acts as 
a direct antioxidant by scavenging ROS and it is used for 
its anti-cytokine and neuroprotective action in 
amyotrophic lateral sclerosis. It is considered an orphan 
drug  [147] and in a phase II study has been 
demonstrated a slower decline in patient treated with 
edaravone [148], although its efficacy has not been 
completely demonstrated, according to a recent study 
[149]. Edaravone has been also used in cardiovascular 
disease and in the prevention of atherosclerosis for its 
capacity to reduce lipid peroxidation and monocyte 
adhesion to vascular endothelium.  
Edaravone has been tested in a model of anxiety in rats 
induced by the administration of bacterial 
lipopolysaccharide; its administration could revert the 
anxiety-like response in the EPM.  [150] 
In a model of chronic restrain stress, edaravone could 
ameliorate the oxidative stress response measured by 
enzyme activity and glutathione concentration in 
hippocampus and prefrontal cortex and it could also 
reverse the anxiety-like behaviour in the EPM [151], 
suggesting an effect exerted essentially by 
neuroprotection. 
4.6.2 MitoQ 
MitoQ is the most characterized mitochondrial acting 
compound and is composed by a quinone linked to a 
triphenylphosphonium (TTP) with an alkyl chain  [152]. 
This compound exerts its effect passing the 
mitochondrial membrane, due to the TTP moiety, which 
permits an accumulation in the mitochondria [152]. 
After passing the membrane the quinone moiety is 
converted by the succinate dehydrogenase in the active 
antioxidant form of ubiquinol, which detoxifies ROS 
yielding H-ion and it is than converted in ubiquinone. 
Succinate dehydrogenase converts the ubiquinone in 
ubiquinol, permitting the recycling of the antioxidant 
and blocking the lipid peroxidaxion  [153]. Furthermore, 
the reduced form ubiquitinone is slowly oxidized by the 
complex III, switching the reaction to succinate 
dehydrogenase and increasing the antioxidant efficacy 
[154].  
MitoQ has been tested in animal models of neurological 
diseases such as Hungtington Disease [155] and in a 
phase 2 trial on Parkinson disease [156].  
In a recent study by Nussbaumer et al MitoQ has been 
shown to reduce anxiety-like behaviour in genetically 
modified HAB-mice but not in LAB-mice, suggesting a 
selectivity for anxiety disorder [157]. Although these 
results are interesting, the effectiveness of MitoQ should 
be analysed in other anxiety models, for example using 
non inbred mice, and the response difference between 
HAB and LAB mice should be clarified on a greater 
sample. 
4.6.3 Minocycline 
Minocycline is a second generation tetracycline 
derivative, introduced as an antimicrobial agent in 1967 
[158, 159], which can also be considered belonging to 
the class of phenolic antioxidants, for the presence in its 
molecule of a mulch-substituted phenolic ring, similar 
to that of ɑ-tocopherol [160]. Minocycline can pass the 
BEE and exerts neuroprotective effect by different 
mechanisms, beyond the antioxidant one  [161]. It has 
an anti-apoptotic effect, either in a caspase-dependent or 
in a caspase-independent manner: it reduces the release 
of pro-apoptotic factors from the mitochondria and 
increases the release of anti-apoptotic factors. It reduces 
inflammation, for example by suppression of microglial 
activation, inhibition of pro-inflammatory cytokines and 
inhibition of MMPs. Furthermore, minocycline can 
modulate the glutamatergic transmission, probably 
acting on the kinurenine pathway and thus reducing the 
production of the NMDA agonist QUIN; it can also act 
indirectly on the monoamine system [162].  
Given its targets, minocycline has been studied for its 
possible use in psychiatric disorders. In 1996, Levine 
wrote a case report that suggested the possible 
antidepressant effect of minocycline in a patient with 
catatonic schizophrenia [163]. Then the antidepressant 
effect of minocycline has been studied though animal 
models as the Forced Swimming Test (FST) [164]. It has 
also been proven to be effective in improving cognitive 
deficits in a murine model of schizophrenia, achieved by 
administration of phencyclidine [165].  
Furthermore, animal studies have also suggested that 
minocycline can act on anxiety symptoms [166]. 
Neigh et al have shown that pre-treatment with 
minocycline was able to reduce the anxiety-like 
behaviour and the neuronal damage in mice undergoing 
8 min of cardiac arrest/cardiopulmonary resuscitation 
(CA/CPR). Since the anxiety-like behaviour correlated 
with the microglial activation, it seemed that the 
anxiolytic action of minocycline was linked to 
modulation of inflammation resulting from cerebral 
ischemia [167].  
Kovesdi et al investigated the effect of minocycline 
treatment on the neurobehavioural modifications 
induced by mild traumatic brain injury in rats. The 
animals were subjected to behavioural tests before the 
injury and after (8 and 45 days); select markers of 
inflammation, and of vascular, neuronal or glial damage 
were measured in serum and brain regions linked to 
memory and anxiety, 52 days after the injury.. 
Minocycline treatment prevented the anxiety increase at 
the EPM 45 day after the injury, but not 8 days after, and 
normalized serum and tissue levels of the examined 
markers  [168].  
Jarrett investigated whether minocycline, thanks to its 
ability to suppress the microglial activation, could 
prevent the alterations in immune function and anxiety-
like behaviour, resulting from the administration of a 
Repeated Social Defeat (RSD) stress in C57bl/6 mice. 
The administration of minocycline, beginning two days 
before the stress, was found to prevent: the increase in 
macrophage trafficking to the brain and in circulating 
leukocytes, to reduce the activation of circulating 
monocytes and granulocytes and to prevent the 
induction of an anxiety-like behaviour by the RDS 
stress. The authors therefore suggest that minocycline 
can improve stress-induced anxiety by acting on cell 
activation and redistribution of these immune cells  
[169] . 
Majidi et al treated neonatal mice with 
lipopolysaccharide to assess whether minocycline 
developmental treatment could reduce the abnormalities 
in adulthood, induced by an early-life insult. 
Minocycline was found to have positive effects on 
anxiety and depressive-like symptoms, HPA 
hyperactivity and increased levels of proinflammatory 
cytokines in the hippocampus, due to the early-life stress 
[170].  
In contrast with the results of the studies described 
above, a recent study by Vogt doesn't confirm the 
protective effect of minocycline against anxiety. Vogt et 
al conducted tests of depression and anxiety, such as the 
FSP, DLB and OF in adult C57bl/6 mice. In mice treated 
with minocycline 20-40 mg/kg i.p, it did no occur a 
change in depressive- and anxious- like behaviours, 
unlike what happened with the administration of 
imipramine or diazepam. However, the authors do not 
exclude that minocycline a higher dosage could have an 
effects in the behavioural tests and a clinical effect on 
mood disorder as add-on therapy  [171].  
These animal studies have been followed by different 
clinical trials on the potential use of minocycline for the 
pharmacological treatment of psychiatric disorders. 
Utari et al provide a first survey on the effects of 
minocycline on children with X-fragile syndrome. The 
study took into account the 50 patients that were treated 
with minocycline for at least 2 weeks, with a mean 
treatment duration of 3.5 months at a dosage of 20-200 
mg/day. The results of treatment were evaluated through 
questionnaires administrated to parents that used Likert 
scale to assess the patients' changes in different areas. 
Among the areas, in which parents noticed a greater 
improvement there were anxiety, social communication, 
attention and language [159].  
In a randomized placebo-controlled double-blind 
clinical trial, minocycline exerted a beneficial effect on 
negative symptoms of early schizophrenia, but this trial 
presents several limitations, including the small number 
of patients, that don't allow to clearly establish its 
effectiveness [172].  
Additional clinical trials on the possible effectiveness of 
minocycline in schizophrenia and depression are 
underway and some have as a secondary outcome the 
evaluation of its effect on anxiety symptoms [173, 174].  
4.7 Endogenous antioxidants 
4.7.1 Melatonin 
Melatonin is produced by the pineal gland and is 
involved in circadian rhythm and cell signalling. It has a 
recognized antioxidant effect by stimulating the 
synthesis of GSH and its metabolites acetyl formyl 
kinuramine and acetyl kinuramine have a ROS 
scavenging activity [175]. The prevalent therapeutic use 
of this molecule is the sleep disturbances that often are 
in comorbidity with anxiety disorders [176]. Melatonin 
has shown an ameliorating rating of the Hamilton 
anxiety scale score, in patients with sleep disturbances 
and breast cancer [177], but anxiety was assessed as an 
outcome in patients with psychiatric illness depending 
by clinical conditions. In the methanalysis by Hansen et 
al, authors consider melatonin effective as a 
premedication in pre and post operative anxiety and it is 
considered safe and effective in paediatric patient 
undergoing medical procedures [178].  
A phase 3 trial is ongoing for the valuation of melatonin 
as an add on medication in patient with anxiety and 
depression in comorbidity with breast cancer.  
In preclinical studies, melatonin has been observed to 
reduce oxidative stress in coadministration with 
buspirone in a model of contention stress [179]. 
In a model of anxiety induced by intraperitoneal 
injection of E. coli lipopolysaccharides, the anxiety-like 
behaviour, evaluated by EPM, was reduced by the 
administration of luzindole, an antagonist of the 
melatonin receptor [180], although this model of anxiety 
induction is more similar to concomitant anxiety in other 
clinical condition. It has been also observed that intra-
amygdaloid al melatonin injection in pineleactomized 
rats improves the time spent in the open arm in the EPM 
test [181]; melatonin can also revert behavioural 
alterations induced by diisonyl-phthalate, by enhancing 
oxidative stress [182]. 
To our knowledge there are no data about melatonin in 
more specific animal models and on patients with 
anxiety non associated to other medical conditions.  
Agomelatine instead, an antidepressant based on 
melatonin function, has a confirmed effectiveness 
versus placebo in a randomized controlled trial on 
patient with GAD [183]; recently it has been shown that 
agomelatine can increase SOD activity in rats striatum 
and catalase activity in cerebellum but no influence has 
been reported on lipid peroxidation and brain 
carbonylation [184].  
 
5. Conclusions 
Increased levels of oxidative stress have been associated 
with a wide range of CNS disorders, including anxiety 
disorders. An anxiolytic activity of of oxidative stress 
modulators has been widely demonstrated in rodents, 
whereas data obtained in humans are less clear. A 
number of factors should be considered when comparing 
preclinical and clinical data. For example, most of the 
animal models of anxiety do not recapitulate the 
complexity of anxiety disorders in humans, i.e., the 
same model has not construct, face, and 
pharmacological validity at the same time. Anxiety in 
humans is strongly influenced by the personal history 
(particularly early life experiences) and social context  
[185], whereas most of preclinical data were obtained in 
normal rats or mice exposed to a conflicting situation 
(e.g., light-dark box or elevated plus maze) or exposed 
to natural threats (in which fear response can be 
considered as defensive, and, therefore, 
“physiological”). According to some Authors oxidative 
stress and anxiety in humans might be associated 
without a clear cause-effect relationship [186].Perhaps 
several clinical studies with antioxidants did not produce 
positive results because there other factors contributing 
to the pathogenesis of anxiety are insensitive to 
antioxidants [187].Another possibility is that ROS in 
humans may be physiologically important [187], and the 
broad-spectrum antioxidant drugs used in clinical 
studies do not distinguish between physiological and 
pathological actions of ROS and other oxidative species. 
Other limiting factors in human studies are the route of 
administration and the doses and time of administration 
of antioxidants, which may not reach the clinically 
effective concentrations in the CNS [187].It is always 
difficult to find a right dose of an antioxidant in humans, 
which maintains an optimal risk-to-benefit ratio by 
restraining the toxic effects of ROS without interfering 
with their physiological activity  [188].Last, but not 
least, the inclusion criteria in clinical studies did not take 
into account the presence of specific biomarkers of 
oxidative stress  [187].  
Despite these potential limitations of human studies, the 
evidence of efficacy of some oxidative stress modulators 
in rodents is encouraging and further stimulate 
translational research. 
Interestingly, some putative oxidative stress modulators 
produce anxiolytic effect via mechanisms other than a 
classical antioxidant mechanism. NAC, for example, 
activates the cysteine-glutamate antiporter leading not 
only to an increase in intracellular cysteine (and, 
therefore, to GSH synthesis), but also to an increase in 
extracellular glutamate. This in turn activates type-2 
metabotropic glutamate receptors in the preterminal 
region of the axon, thereby reducing glutamate release 
from nerve terminals  [189]. Of note, mGlu2 receptors 
are targets for the treatment of anxiety and drug 
addiction  [190, 191]. 
We believe that the development of an oxidative 
stress-modulating therapy in anxiety disorders 
could be beneficial as an add-on therapy 
integrating conventional psychotherapeutic and 
pharmacological approaches. The effectiveness of 
an additional therapeutic strategy could be useful 
given the limitations of the current therapies, for 
example the latency time of selective serotonin 
reuptake inhibitors(SSRIs) and the potential of 
abuse of benzodiazepines.  
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